Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.


TSXV:COV - Post by User

Bullboard Posts
Post by TheRock07on Aug 09, 2016 9:49am
174 Views
Post# 25122195

Another Contract Win...$11.1 + million in just 2 weeks

Another Contract Win...$11.1 + million in just 2 weeksAs I said in a post one or two days ago, we are going to be seeing a steady string of these Middle East contracts.

COV won 14 tenders in 2015, pilot tests more or less which we are now seeing being converted to solid contracts.

 

This contract award of a minimum of $3.5 million  is massively significant for Covalon in Saudi Arabia and further strengthens Covalon as a major player in the Middle East.

Covalon fully expect to leverage the minimum commitment of $3.5 million into additional IV Clear revenue in Saudi Arabia. The win validates Covalon’s antimicrobial technology and will help us secure other contracts in the region and world-wide.


Those who remain non believers that they will build Covalon into a $1 billion company over the next 4 years outa rethink their strategy and hop aboard.

I am a strong believer that it will be delivered..
Bullboard Posts